The orthopedic devices industry is increasingly being shaped by a relatively concentrated group of global companies that compete across joint replacement, trauma, spine, sports medicine, surgical robotics, navigation, biologics, and digital surgical technologies.
The most important competitive change is that companies are moving beyond selling individual implants. The industry is becoming a contest over complete surgical ecosystems—combining implants, robotics, planning software, navigation, instruments, data, surgeon training, and recurring consumables.
Download Sample https://www.precedenceresearch.com/sample/1027
Based on recent company financial disclosures, the scale difference between the major players remains significant. Johnson & Johnson’s Orthopaedics franchise generated $9.258 billion in 2025, Stryker reported $6.110 billion in Orthopaedics sales, Zimmer Biomet generated $8.232 billion in total company sales, and Smith+Nephew generated $2.437 billion from its Orthopaedics business. These figures are not perfectly comparable because companies report different business segments, but they illustrate the financial weight of the industry’s leading competitors.
Who Are the Companies Setting the Competitive Direction?
The orthopedic devices industry is led by a combination of diversified medical technology giants and highly specialized musculoskeletal companies.
The major competitive group includes:
- Johnson & Johnson MedTech / DePuy Synthes
- Stryker
- Zimmer Biomet
- Smith+Nephew
- Enovis
- Globus Medical
- Arthrex
- CONMED
Industry estimates indicate that the top five companies hold a substantial portion of the orthopedic devices industry, highlighting the importance of scale, established surgeon relationships, distribution networks, clinical evidence, and technology investments.
What Makes Johnson & Johnson’s DePuy Synthes Strategy Different?
Johnson & Johnson is potentially creating one of the most significant structural changes in orthopedic devices.
Its Orthopaedics franchise generated approximately $9.3 billion in sales during 2025. The portfolio covers major categories including:
- Hip reconstruction
- Knee reconstruction
- Trauma
- Spine
- Sports medicine
- Digital and robotic-assisted surgical technologies
However, the biggest strategic development is Johnson & Johnson’s plan to separate its Orthopaedics business, which is expected to operate as DePuy Synthes.
The company stated that the proposed standalone business would focus specifically on orthopaedics and would operate across a global sector opportunity exceeding $50 billion, while serving approximately seven million patients annually.
Why is the separation important?
A standalone DePuy Synthes could potentially make faster strategic decisions around:
- Orthopedic acquisitions
- Robotics and digital surgery
- Implant innovation
- Manufacturing efficiency
- Surgeon-focused commercial strategies
The company is also dealing with challenges. In 2025, its Orthopaedics business experienced disruption associated with restructuring, while volume-based procurement in China and pricing pressure affected performance.
Company insight
The separation could transform DePuy Synthes from being one business inside a diversified healthcare conglomerate into a pure-play orthopedic giant.
Strategic direction: Scale + portfolio breadth + robotics + operational restructuring.
How Is Stryker Building an Orthopedic Technology Ecosystem?
Stryker remains one of the strongest companies in orthopedic devices because of its ability to connect implants with enabling technology.
For 2025, the company’s total Orthopaedics sales were approximately $6.110 billion, including:
| Business category | 2025 sales |
|---|---|
| Knees | $2.768 billion* |
| Hips | Included in U.S. and international Orthopaedics reporting |
| Trauma & Extremities | Major growth category |
| Spinal Implants | Reported separately within Orthopaedics |
| Other orthopedic products | Additional portfolio contribution |
*Stryker reports product categories across U.S. and international tables, so category totals should be interpreted according to its segment reporting structure. Total Orthopaedics sales reached $6.110 billion in 2025.
One of Stryker’s most important competitive assets is its Mako SmartRobotics platform.
What gives Stryker an advantage?
The company’s strategy is not simply to sell a knee or hip implant. The larger opportunity is to connect:
Robot → surgical planning → implant → procedure → hospital relationship
This creates a stronger technology ecosystem and can increase switching costs for hospitals and surgeons.
Stryker’s 2025 results also showed strong Orthopaedics momentum, with fourth-quarter organic sales growth of 8.4%.
Company insight
Stryker’s biggest strength is its ability to combine a large implant portfolio with robotic-assisted surgery.
Strategic direction: Robotics + reconstruction + trauma + recurring procedure ecosystem.
Why Is Zimmer Biomet Expanding Beyond Traditional Joint Replacement?
Zimmer Biomet remains one of the industry’s major reconstruction companies.
The company generated $8.232 billion in net sales during 2025, representing 7.2% reported growth and 3.9% organic constant-currency growth.
Zimmer Biomet’s competitive strategy increasingly centers on transforming itself from an implant-focused company into a broader orthopedic technology platform.
Where is the company investing?
Its strategy increasingly includes:
- Robotic-assisted surgery
- Digital surgery
- Knee and hip reconstruction
- Sports medicine
- Extremities
- Trauma
- Foot and ankle technologies
The company’s technology strategy is particularly important because traditional joint replacement companies are under pressure to differentiate through surgical workflow rather than implant design alone.
Why does robotics matter for Zimmer Biomet?
Robotic and digital systems can create a long-term connection between:
- Hospitals
- Surgeons
- Surgical planning
- Implant selection
- Zimmer Biomet products
This can make the technology platform strategically more important than any individual implant.
Strategic direction: Joint replacement leadership + robotics + digital surgery + portfolio expansion.
How Has Smith+Nephew Turned Orthopaedics Into a Growth Priority?
Smith+Nephew has undergone a significant operational transformation.
The company’s Orthopaedics revenue reached $2.437 billion in 2025, compared with $2.305 billion in 2024, representing 5.7% reported growth and 5.1% underlying growth.
This is important because Smith+Nephew has spent several years addressing supply issues, improving productivity, and rebuilding Orthopaedics growth.
What is driving the company?
The Orthopaedics business includes:
- Knee implants
- Hip implants
- Trauma
- Extremities
- Reconstruction technologies
The company also has a significant competitive advantage through its position in sports medicine, where its products and surgeon relationships provide opportunities for cross-category growth.
Smith+Nephew has highlighted the upcoming LANDMARK Knee System as part of its strategy to combine advanced kinematics, personalization, robotic enablement, and existing instrumentation.
Company insight
Smith+Nephew’s story is increasingly one of operational recovery.
The company is trying to demonstrate that improving execution can generate growth without relying entirely on major acquisitions.
Strategic direction: Operational turnaround + sports medicine leadership + personalized and robotic-enabled reconstruction.
What Is Enovis Doing to Challenge the Larger Orthopedic Companies?
Enovis is smaller than the largest orthopedic giants but is becoming increasingly important through acquisitions and reconstructive orthopedics.
The company generated approximately $2.2 billion in total net sales in 2025. Its Reconstructive business grew 10% on a reported basis and 8% organically.
The integration of LimaCorporate is particularly important to Enovis’ orthopedic strategy.
Why is Enovis a company to watch?
Its growth strategy combines:
- Joint reconstruction
- Personalized orthopedic solutions
- Digital planning
- International expansion
- Prevention and recovery technologies
Unlike the largest companies, Enovis is still actively building scale in orthopedics.
This creates both opportunity and risk.
The company reported substantial non-cash goodwill impairment charges in 2025, demonstrating that rapid portfolio expansion also creates integration and financial execution challenges.
Company insight
Enovis represents the industry’s challenger model: grow aggressively through acquisitions while building differentiated reconstructive technologies.
Strategic direction: Acquisition-led scale + personalized reconstruction + international expansion.
How Is Globus Medical Changing the Spine and Musculoskeletal Technology Race?
Globus Medical has become one of the most technology-driven companies in musculoskeletal devices.
The company reported approximately $2.939 billion in net sales in 2025, compared with $2.519 billion in 2024.
Its strength is particularly visible in:
- Spine
- Trauma
- Musculoskeletal solutions
- Surgical navigation
- Robotic-assisted surgery
- Enabling technologies
The company’s ExcelsiusGPS platform represents an important example of where orthopedic competition is heading: hardware, implants, navigation, and software operating as one ecosystem.
During the fourth quarter of 2025, Globus reported strong growth in its legacy musculoskeletal business, including growth in enabling technologies and trauma.
Company insight
Globus Medical is one of the clearest examples of a company competing through engineering and enabling technology rather than relying primarily on traditional implant scale.
Strategic direction: Spine leadership + robotics + navigation + integrated surgical technology.
Why Does Arthrex Remain a Major Competitive Force Without Being Publicly Traded?
Arthrex is particularly important because it operates differently from publicly traded competitors.
The company remains privately held and has built a powerful position in:
- Arthroscopy
- Sports medicine
- Minimally invasive orthopedics
- Trauma
- Orthobiologics
- Spine
- Arthroplasty
- Surgical visualization
Arthrex states that it develops more than 1,000 new products and related procedures annually.
What is its competitive advantage?
Because Arthrex is privately held, it does not report financial results in the same way as public companies. However, its competitive importance is clear from its innovation intensity and strong position in sports medicine.
Its strategy is based heavily on:
Innovation → surgeon education → procedural adoption → product expansion
This is particularly powerful in sports medicine, where surgeon familiarity and procedural training can significantly influence product adoption.
Strategic direction: Innovation intensity + minimally invasive surgery + surgeon education.
What Makes CONMED Important in the Specialized Orthopedic Segment?
CONMED demonstrates that specialized companies can compete effectively against much larger medical technology groups.
The company’s Orthopedic Surgery business generated approximately $574.6 million in 2025, growing 5.6% on a reported basis and 5.5% on a constant-currency basis.
Its orthopedic portfolio focuses on:
- Sports medicine
- Soft tissue repair
- Arthroscopy
- Powered surgical instruments
- Foot and ankle
- Biologics and fixation
A particularly interesting business characteristic is that approximately 78% of its Orthopedic Surgery revenue in 2025 came from single-use products.
Why does this matter?
Recurring single-use products can provide a different revenue model compared with companies that depend heavily on major capital equipment or large implants.
Strategic direction: Sports medicine specialization + recurring consumables + minimally invasive procedures.
Which Companies Have the Strongest Competitive Positions?
| Company | Major strength | Key strategic focus |
|---|---|---|
| Johnson & Johnson / DePuy Synthes | Scale and broad orthopedic portfolio | Separation and focused orthopedics strategy |
| Stryker | Robotics and reconstruction | Connected surgical ecosystem |
| Zimmer Biomet | Joint replacement scale | Digital surgery and robotics |
| Smith+Nephew | Sports medicine and improving Orthopaedics | Operational recovery and innovation |
| Enovis | Acquisition-led expansion | Personalized reconstruction |
| Globus Medical | Spine and enabling technology | Robotics and navigation |
| Arthrex | Sports medicine innovation | Minimally invasive procedures |
| CONMED | Specialized orthopedic products | Recurring procedural revenue |
Where Is Competition Becoming the Most Intense?
The strongest competitive battles are increasingly occurring in five areas.
1. Robotic-assisted surgery
Companies including Stryker, Zimmer Biomet, Smith+Nephew, Johnson & Johnson, and Globus Medical are competing to integrate technology into surgical workflows.
The winner may not necessarily be the company with the best implant alone.
It may be the company that owns the entire surgical workflow.
2. Personalized orthopedic procedures
Companies are increasingly investing in:
- Patient-specific planning
- Personalized implants
- Advanced imaging
- Digital surgical workflows
This could move orthopedic devices toward more customized treatment models.
3. Sports medicine
Sports medicine remains strategically important because procedures are often minimally invasive and involve significant recurring product demand.
Arthrex, Smith+Nephew, Stryker, and CONMED are particularly important competitors in this area.
4. Trauma and extremities
Trauma, foot and ankle, and extremity procedures are becoming important expansion categories for companies seeking growth beyond traditional hip and knee replacement.
5. Acquisitions and portfolio building
Enovis, Globus Medical, and other competitors demonstrate that acquisitions remain a major way to acquire technology, expand geographic reach, and enter new orthopedic categories.
How Will Company Strategies Change the Industry?
The next phase of competition is likely to be defined by technology ecosystems rather than individual devices.
The most successful companies will increasingly need to offer combinations of:
- Implants
- Robotics
- Navigation
- Software
- Digital planning
- Imaging
- Surgical instruments
- Data
- Surgeon education
- Recurring procedural products
This could create a competitive divide.
Large companies such as DePuy Synthes, Stryker, and Zimmer Biomet have the financial scale to build comprehensive ecosystems. Meanwhile, companies such as Arthrex, Globus Medical, Enovis, and CONMED can compete through specialization, engineering, procedural expertise, acquisitions, or faster innovation cycles.
Buy This Report https://www.precedenceresearch.com/checkout/1027
About Us
Healthcare Prism is a dedicated healthcare insights and outreach platform, operating as an extension of Precedence Research. We share relevant perspectives, industry developments, emerging trends, and research-driven insights across the global healthcare sector. Our content is built on the knowledge, research standards, and expertise of Precedence Research, with a focus on making healthcare information clear, accessible, and useful for industry professionals, businesses, researchers, and healthcare stakeholders. Healthcare Prism serves as a focused platform to extend the reach of Precedence Research’s healthcare insights and connect them with a broader professional audience.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Quick Contact:
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04 and +65 31065601
Visit Our Website: https://www.precedenceresearch.com